By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market Monday that its third-quarter revenues increased 17 percent year over year, and the firm posted a profit for the second quarter in a row.

The Redwood City, Calif.-based pharmacogenomic test maker brought in total revenues of $46.3 million, compared to revenues of $39.5 million for the third quarter of 2009. It beat analysts' consensus estimate of $44.9 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.